Related Experiment Video
Updated: May 31, 2026
Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
Published on: March 10, 2020
Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening
Min-Chul Cho1, Dong-Hun Lee, Eun Jin Kim
1Department of Bioscience and Biotechnology, Laboratory of Cell Biology and Immunobiochemistry, Bio/Molecular Informatics Center, Konkuk University, Hwayang-dong 1, Gwangjin-gu, Seoul 143-701, Republic of Korea.
Abstract:
Peroxisome proliferator-activated receptors (PPARs) are the transcriptional factor that regulate glucose and lipid homeostasis and widely well-known as molecular targets for improvement of metabolic disorder. Because major transcriptional activity of PPARs depends on their proper ligands, the studies for PPAR ligands have been continuously developed. We previously reported the simple enzyme-linked immunosorbent assay (ELISA) systems to screen PPAR ligands and a chemical library including flavonoid derivatives have applied to these systems. In this study, we introduce two compounds (KU16476 and KU28843) identified as PPARγ partial agonists by a screening ELISA for PPARγ ligand. KU16476 and KU28843 significantly increased binding between PPARγ and SRC-1 in a simple ELISA system. Co-activator recruiting-induced abilities of two compounds were less than that of indomethacin, a well-known PPARγ agonist. To determine whether these compounds would be PPARγ partial agonists, each candidate with indomethacin were applied to a simple ELISA based on binding between PPARγ and SRC-1. Cotreatment with indomethacin significantly increased binding between PPARγ and SRC-1 than treatment of indomethacin or candidate alone. Two compounds had no considerable cytotoxicities, induced partial adipogenesis, and accumulated lipid droplets in 3T3-L1 fibroblast. Also, these two compounds enhanced expression of PPARγ-mediated genes such as aP2 and UCP-2. By docking study, we confirmed that two compounds bound well to the active site of PPARγ with hydrophobic interactions. We suggest that two compounds identified by a simple ELISA system can be PPARγ partial agonists. These PPARγ partial agonists and these studies to find out novel PPARγ agonists may contribute to drug development against metabolic disorders.
Insights
Two novel compounds, KU16476 and KU28843, were identified as peroxisome proliferator-activated receptor gamma (PPARγ) partial agonists. These compounds show potential for developing new drugs to treat metabolic disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Peroxisome proliferator-activated receptors (PPARs) are key regulators of glucose and lipid metabolism, making them important targets for metabolic disorder treatments.
- Ligand identification is crucial for PPARs' transcriptional activity, driving continuous research in this area.
- Previous work established simple enzyme-linked immunosorbent assay (ELISA) systems for screening PPAR ligands, including flavonoid derivatives.
Purpose of the Study:
- To identify and characterize novel partial agonists for Peroxisome proliferator-activated receptor gamma (PPARγ).
- To evaluate the potential of identified compounds as therapeutic agents for metabolic disorders.
Main Methods:
- Screening of a chemical library using a simple ELISA system to identify PPARγ ligands.
- Assessing co-activator recruitment ability by measuring binding between PPARγ and SRC-1.
- Evaluating compound effects on adipogenesis and lipid droplet accumulation in 3T3-L1 fibroblasts.
- Analyzing the expression of PPARγ-mediated genes (aP2, UCP-2).
- Confirming binding interactions using molecular docking studies.
Main Results:
- Two compounds, KU16476 and KU28843, were identified as PPARγ partial agonists via ELISA.
- These compounds enhanced PPARγ and SRC-1 binding, with partial co-activator recruitment compared to indomethacin.
- KU16476 and KU28843 demonstrated no significant cytotoxicity, induced partial adipogenesis, and accumulated lipid droplets.
- Gene expression analysis showed enhanced PPARγ-mediated genes (aP2, UCP-2).
- Docking studies confirmed favorable hydrophobic interactions within the PPARγ active site.
Conclusions:
- KU16476 and KU28843 are confirmed as PPARγ partial agonists, identified through a simple ELISA screening system.
- These compounds exhibit biological activity consistent with partial agonism, including effects on adipogenesis and gene expression.
- The identified PPARγ partial agonists and the screening methodology hold promise for future drug development against metabolic disorders.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...